A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Stopped Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.
Conditions
- Pancreatic Cancer
- Resectable Pancreatic Cancer
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma
Interventions
- DRUG: mFOLFIRINOX
- DRUG: 5-Fluorouracil (5-FU)
- DRUG: Oxaliplatin
- DRUG: Irinotecan
- DRUG: Leucovorin
- DRUG: NIS793
- RADIATION: Chemoradiation
- PROCEDURE: Surgery
Sponsor
Kimberly Perez, MD
Collaborators